Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


NetScientific picks up ProAxsis
QUB spinout ProAxsis has been fully acquired by NetScientific, which previously backed the company’s sole funding round in 2014.
Astellas takes an Iota in acquisition deal
The UC Berkeley spinout has been snapped up by Astellas, two years after the latter took part in its series A round.
Disarm hands itself to Eli Lilly
Eli Lilly will acquire the WUSTL-linked neurological disease therapy developer in a $135m deal that could top $1.2bn with milestone payments.
Nanofilm rolls towards stock market
NTU spinout Nanofilm Technologies has seemingly filed a draft prospectus with a view of listing on the domestic Singapore Stock Exchange.
Codiak Biosciences cracks IPO code
Codiak – based on research at Gothenburg and MD Anderson Cancer Center – has succeeded in going public after previously cancelling plans.
Kronos Bio crushes IPO to raise $250m
MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.
Galecto elects to target $100m in IPO
Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.
Gamma Biosciences absorbs Nanopareil
Nanopareil employs nanofibre membranes to separate chemical compounds for the purposes of purifying biopharmaceutical candidates.

Other News

Momentus finds Stable Road to Nasdaq
University of Wyoming-backed Momentus is set to merge with SPAC Stable Road Acquisition in a deal that values the space infrastructure company at $1.2bn.
Kronos Bio casts IPO range
MIT's cancer therapy developer has set terms for an offering that will raise more than $185m if it floats at the top of its range.
Readcoor agrees to $350m acquisition
10x Genomics has bought Harvard's genetic sequencing system provider and also revealed it closed its purchase of Stockholm University spinout CartaNA.
C4 Therapeutics blows on to public markets
Dana-Farber Cancer Institute's cancer therapy developer raised $182m in an upsized IPO where it floated above its range.
Jamespot to combine with Open Agora
Satt Erganeo-backed Open Agora offers software to run opinion surveys within enterprise software such as Slack.
Snyk executes purchase of DeepCode
The ETH Zurich software security spinout had raised at least $5.2m before it was purchased by Snyk yesterday for an undisclosed sum.

Editor's Picks

Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg